Sirolimus-induced leukocytoclastic vasculitis

Transplantation

Volumn 74, Issue 5, 2002, Pages 739-740

  Hardinger, Karen L ^a   Cornelius, Lynn A ^a   Trulock III, Elbert P ^a   Brennan, Daniel C ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTOCLASTIC VASCULITIS; LUNG TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037106488     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200209150-00025     Document Type: Article

References (5)

1. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000;356:194.
2. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271.
3. Rapamune (sirolimus) [package insert]. Philadelphia, Wyeth Laboratories 2001.
4. Gibson LE. Cutaneous vasculitis update. Dermatol Clin 2001;19:603.
5. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: a pathophysiological approach, ed. 4. Norwalk, Appleton & Lange 1999, page 1510.02